Chakraborty, R
Muchtar, E
Kumar, S http://orcid.org/0000-0001-5392-9284
Buadi, F K
Dingli, D
Dispenzieri, A
Hayman, S R
Hogan, W J
Kapoor, P
Lacy, M Q
Leung, N http://orcid.org/0000-0002-5651-1411
Gertz, M A
Article History
Received: 20 April 2016
Revised: 14 June 2016
Accepted: 8 July 2016
First Online: 22 August 2016
Competing interests
: S Kumar: Celgene (Consultancy and Research Funding), Millennium (Consultancy and Research Funding), Novartis (Research Funding), Onyx (Consultancy and Research Funding), AbbVie (Research Funding), Janssen (Consultancy and Research Funding) and BMS (Consultancy and Research Funding); A Dispenzieri: research funding (Celgene, Millennium, Pfizer and Janssen) and travel grant (Pfizer); P Kapoor: research funding from Millennium (Takeda), Celgene and Onyx (Amgen); MQ Lacy: research funding (Celgene); MA Gertz: Celgene (Honoraria), Millenium (Consultancy and Honoraria), Onyx (Honoraria), Novartis (Honoraria) and Smith Kline (Honoraria). The remaining authors declare no conflict of interest.